General Medicines, Commercial Director, Menopause
Pfizer
September 02, 2026
Remote friendly (Pennsylvania, United States)
United States
Sales
Responsibilities:
- Own menopause portfolio strategy (franchise and brand-level) using customer insight, performance targets, and market realities.
- Serve as brand steward: connect cross-functional teams, clarify decisions, and remove roadblocks.
- Enable a first-in-industry partnership model by aligning internal/external stakeholders.
- Lead externalized content development end-to-end, including MLR, ensuring HCP/patient materials are strategic, compliant, and delivered on time.
- Manage day-to-day engagement with 3rd-party partner (Indegene) across menopause brands.
- Drive portfolio prioritization across initiatives and investment; make trade-offs to maximize impact.
- Set and deliver commercial strategy, aligning brand plans to PAVE priorities and enterprise goals; convert strategy into measurable execution.
- Build and align stakeholder network (medical, access, legal/regulatory, agency/partners, etc.) to achieve brand goals.
- Share learnings and drive simplification/efficiencies within the broader PAVE community.
- Act as a visible, trusted leader with strong judgment and storytelling.
Qualifications (Minimum):
- BA/BS + 8 yrs, MBA/MS + 7 yrs, PhD/JD + 5 yrs, or MD/DVM + 4 yrs.
- Brand management experience.
- Proven track record in pharmaceutical commercial strategy development.
- Strong analytical skills; interpret complex data.
- Experience leading cross-functional teams; excellent project management.
- Market analysis and forecasting proficiency.
- Familiarity with pharmaceutical regulatory requirements.
- Stakeholder engagement/relationship management expertise.
- Proficiency using GCMA for promotional materials review/approval.
- Openness to using AI tools.
Preferred:
- Leadership focused on stakeholder engagement.
- Adaptability, strategic/proactive problem-solving, communication/presentation skills.
- Patient-centric approach; collaboration/influence/negotiation.
- High emotional intelligence; resilience.
Travel: 10%.
Apply by: September 16, 2026.
- Own menopause portfolio strategy (franchise and brand-level) using customer insight, performance targets, and market realities.
- Serve as brand steward: connect cross-functional teams, clarify decisions, and remove roadblocks.
- Enable a first-in-industry partnership model by aligning internal/external stakeholders.
- Lead externalized content development end-to-end, including MLR, ensuring HCP/patient materials are strategic, compliant, and delivered on time.
- Manage day-to-day engagement with 3rd-party partner (Indegene) across menopause brands.
- Drive portfolio prioritization across initiatives and investment; make trade-offs to maximize impact.
- Set and deliver commercial strategy, aligning brand plans to PAVE priorities and enterprise goals; convert strategy into measurable execution.
- Build and align stakeholder network (medical, access, legal/regulatory, agency/partners, etc.) to achieve brand goals.
- Share learnings and drive simplification/efficiencies within the broader PAVE community.
- Act as a visible, trusted leader with strong judgment and storytelling.
Qualifications (Minimum):
- BA/BS + 8 yrs, MBA/MS + 7 yrs, PhD/JD + 5 yrs, or MD/DVM + 4 yrs.
- Brand management experience.
- Proven track record in pharmaceutical commercial strategy development.
- Strong analytical skills; interpret complex data.
- Experience leading cross-functional teams; excellent project management.
- Market analysis and forecasting proficiency.
- Familiarity with pharmaceutical regulatory requirements.
- Stakeholder engagement/relationship management expertise.
- Proficiency using GCMA for promotional materials review/approval.
- Openness to using AI tools.
Preferred:
- Leadership focused on stakeholder engagement.
- Adaptability, strategic/proactive problem-solving, communication/presentation skills.
- Patient-centric approach; collaboration/influence/negotiation.
- High emotional intelligence; resilience.
Travel: 10%.
Apply by: September 16, 2026.